A live audio webcast of each presentation will be available on the Investor Relations section of Chimerix's website at www.chimerix.com, where it will be archived for approximately 90 days.
Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing novel antivirals in areas of high unmet medical need. Chimerix's proprietary lipid conjugate technology has produced brincidofovir (BCV, CMX001); CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage compounds. Chimerix is also advancing a clinical candidate for norovirus infection, CMX521. For further information, please visit Chimerix's website www.chimerix.com.
CONTACT: Investor Relations: firstname.lastname@example.org or Will O'Connor Stern Investor Relations Will@sternir.com 212-362-1200 Media: Becky Vonsiatsky
W2O Groupbvonsiatsky@w2ogroup.com 413-478-2003
News Provided by Acquire Media